Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1GA mutation in the dihydropyrimidine dehydrogenase gene
| Autor: | Wolfgang Schwabe, K. Jabschinsky, D. Behnke, C. Terborg, Peter Häusler, J. G. Maring, A. B. P. Van Kuilenburg, H. Schmalenberg, A. Schalhorn |
|---|---|
| Přispěvatelé: | Amsterdam Gastroenterology Endocrinology Metabolism, Cancer Center Amsterdam, Laboratory Genetic Metabolic Diseases |
| Rok vydání: | 2008 |
| Předmět: |
Heterozygote
Dihydropyrimidine Dehydrogenase Deficiency Metabolic Clearance Rate Antineoplastic Agents Pharmacology Biochemistry Capecitabine Pharmacokinetics Neoplasms Genetics medicine Dihydropyrimidine dehydrogenase Humans Dihydrouracil Dehydrogenase (NADP) Chemistry Cancer General Medicine medicine.disease Fluorouracil Area Under Curve Toxicity Mutation Molecular Medicine DPYD Terminal Half Life medicine.drug |
| Zdroj: | Nucleosides, nucleotides & nucleic acids, 27(6), 692-698. Marcel Dekker Inc. |
| ISSN: | 1532-2335 1525-7770 |
| Popis: | 5-Fluorouracil (5FU) and capecitabine are two of the most frequently prescribed chemotherapeutic drugs for the treatment of patients with cancer. Administration of test doses of 5FU to eight patients heterozygous for the IVS14+1G > A mutation and five control patients showed that the AUC and clearance were weak parameters with respect to the identification of patients with a DPD deficiency. However, highly significant differences were observed for the terminal half life of 5FU between DPD patients and controls. Thus, a DPD deficiency could be predicted from 5FU blood concentrations measured after the administration of a test dose of 5FU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|